Last reviewed · How we verify

Antithrombotic agents — Competitive Intelligence Brief

Antithrombotic agents (Antithrombotic agents) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antithrombotic agents. Area: Cardiovascular.

phase 2 Antithrombotic agents Platelet aggregation inhibitors (e.g. P2Y12 receptor, Factor Xa) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Antithrombotic agents (Antithrombotic agents) — Bayer. Antithrombotic agents work by inhibiting platelet aggregation and preventing blood clots.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antithrombotic agents TARGET Antithrombotic agents Bayer phase 2 Antithrombotic agents Platelet aggregation inhibitors (e.g. P2Y12 receptor, Factor Xa)
Conventional antithrombotic strategy Conventional antithrombotic strategy Duk-Woo Park, MD marketed Antithrombotic agents (antiplatelet and/or anticoagulant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antithrombotic agents class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antithrombotic agents — Competitive Intelligence Brief. https://druglandscape.com/ci/antithrombotic-agents. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: